Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Putrescine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Putrescine SCHEMBL5708450 | 1.00 | — | — | |
| Water SCHEMBL27506242 | 0.94 | DNM1 (0.89) | — | |
| Water SCHEMBL1726469 | 0.94 | DNM1 (0.89) | — | |
| Water SCHEMBL5492049 | 0.94 | — | — | |
| Putrescine SCHEMBL19198875 | 0.94 | — | — | |
| Water SCHEMBL28172776 | 0.94 | DNM1 (0.89) | — | |
| Water SCHEMBL31147094 | 0.94 | DNM1 (0.89) | — | |
| Water SCHEMBL27567442 | 0.94 | DNM1 (0.89) | — | |
| Putrescine SCHEMBL21642 | 0.94 | — | — | |
| Putrescine SCHEMBL160836 | 0.94 | NFKB1 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197677-A1 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | VIVIER CANADA INC. (CA) | 2024-06-20 | — | — | US | disclosed |
| WO-2022140706-A1 | IMMUNE-REGULATORY LI-KEY PEPTIDE VACCINES FOR PROPHYLAXIS AND LONG-TERM PROTECTION AGAINST SARS-COV-2 INFECTION AND COVID-19 DISEASE | PURCELL RICHARD D (US) | 2022-06-30 | — | — | WO | disclosed |
| US-9289487-B2 | II-key/antigenic epitope hybrid peptide vaccines | ANTIGEN EXPRESS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140308879-A1 | ADDITIVE FOR POLISHING AGENT, AND POLISHING METHOD | ASAHI GLASS COMPANY, LIMITED (JP) | 2014-10-16 | — | — | US | disclosed |
| CN-104024366-A | Additive for polishing agent, and polishing method | ASAHI GLASS CO LTD | 2014-09-03 | — | — | CN | disclosed |
| US-8815249-B2 | Ii-key/antigenic epitope hybrid peptide vaccines | ANTIGEN EXPRESS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-1212074-B1 | HYBRID PEPTIDES MODULATE THE IMMUNE RESPONSE | ANTIGEN EXPRESS INC (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20100310591-A1 | Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA | ANTIGEN EXPRESS, INC. | 2010-12-09 | — | — | US | disclosed |
| US-20100291145-A1 | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES | ANTIGEN EXPRESS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-1556072-B1 | Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES | ANTIGEN EXPRESS INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-7179645-B2 | Ii-Key/antigenic epitope hybrid peptide vaccines | ANTIGEN EXPRESS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2006076410-A2 | LI-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES | ANTIGEN EXPRESS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060002947-A1 | Ii-key/antigenic epitope hybrid peptide vaccines | NUGENEREX IMMUNO-ONCOLOGY, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1212074-A4 | HYBRID PEPTIDES MODULATE THE IMMUNE RESPONSE | ANTIGEN EXPRESS INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20040058881-A1 | Ii-key/antigenic epitope hybrid peptide vaccines | ANTIGEN EXPRESS, INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030235594-A1 | Ii-Key/antigenic epitope hybrid peptide vaccines | ANTIGEN EXPRESS, INC. (US) | 2003-12-25 | — | — | US | disclosed |
| US-20030091582-A1 | Hybrid peptides modulate the immune response | ANTIGEN EXPRESS, INC. (US) | 2003-05-15 | — | — | US | disclosed |
| US-6432409-B1 | TO ENHANCE THE CHARGING OF SELECTED ANTIGENIC PEPTIDES INTO MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) MOLECULES FOR A VACCINATION TOENHANCE TOXIC RESPONSES AGAINST FOREIGNNESS OF AN INVADING PATHOGEN, OR A TUMOR | ANTIGEN EXPRESS, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1212074-A1 | HYBRID PEPTIDES MODULATE THE IMMUNE RESPONSE | Antigen Express, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001021193-A1 | HYBRID PEPTIDES MODULATE THE IMMUNE RESPONSE | ANTIGEN EXPRESS, INC. (US) | 2001-03-29 | — | — | WO | disclosed |